Use of Raltegravir in Pediatric HIV-1 Infection

Marcia L. Buck, Pharm.D., FCCP, FPPAG; Kristi N. Hofer, Pharm.D; Michelle W. McCarthy, Pharm.D.; FASHP Susan B. Cogut, Pharm.D


Pediatr Pharm. 2012;18(1) 

In This Article

Warnings and Precautions

As with other antiretrovirals, patients beginning therapy with raltegravir should be monitored for immune reconstitution syndrome, an inflammatory response to residual opportunistic infections. These infections may include Mycobacterium avium complex, cytomegalovirus, Pneumocystis jiroveci, Mycobacterium tuberculosis, or reactivation of varicella zoster.[2–5]

Severe dermatologic reactions have been reported in patients receiving raltegravir. These cases have included hypersensitivity reactions, Stevens Johnson syndrome, and toxic epidermal necrolysis. Use of raltegravir should be discontinued immediately in any patient with a severe rash or any rash associated with elevated serum aminotransferases or eosinophilia, or a rash accompanied by fever, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, or angioedema. Families of patients with phenylketonuria should be made aware that the chewable tablet formulations of raltegravir contain phenylalanine.[2–5]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: